Shire PLC (LON:SHP) has been given a consensus rating of “Buy” by the twenty analysts that are currently covering the firm. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is GBX 5,794.29 ($75.63).
Several brokerages have recently weighed in on SHP. Royal Bank Of Canada reiterated an “outperform” rating on shares of Shire PLC in a research report on Wednesday, June 15th. JPMorgan Chase & Co. reiterated an “overweight” rating and set a GBX 6,300 ($82.23) price target (up from GBX 5,600 ($73.10)) on shares of Shire PLC in a research report on Monday, August 1st. Jefferies Group upped their price target on Shire PLC from GBX 6,050 ($78.97) to GBX 6,600 ($86.15) and gave the company a “buy” rating in a research report on Wednesday, August 3rd. Shore Capital reiterated a “buy” rating on shares of Shire PLC in a research report on Tuesday, June 14th. Finally, Deutsche Bank AG reiterated a “buy” rating and set a GBX 6,000 ($78.32) price target on shares of Shire PLC in a research report on Monday, September 19th.
Shire PLC (LON:SHP) opened at 5196.00 on Wednesday. The firm’s 50-day moving average is GBX 4,985.70 and its 200 day moving average is GBX 4,560.67. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00. The company’s market cap is GBX 35.48 billion.
The firm also recently announced a dividend, which was paid on Friday, October 7th. Investors of record on Thursday, September 8th were issued a dividend of GBX 3.51 ($0.05) per share. The ex-dividend date was Thursday, September 8th. This represents a dividend yield of 0.07%.
In other Shire PLC news, insider Dominic Blakemore bought 133 shares of the firm’s stock in a transaction that occurred on Friday, September 30th. The stock was bought at an average price of GBX 5,010 ($65.40) per share, for a total transaction of £6,663.30 ($8,697.69).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.